We found that our anti-OSMR monoclonal antibodies reduced the ovarian cancer cell growth and progression by inhibiting STAT3 activation and subsequent oncogenic signaling operated through STAT3, inhibiting the levels of survival regulators such as BCl2, PCNA, and inducing cell death. Here, PCNA is linked to ovarian cancer.